The Physical Exercise and Prostate Cancer Study (PEPC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00658229 |
Recruitment Status :
Completed
First Posted : April 14, 2008
Last Update Posted : October 15, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer | Behavioral: Strength training group | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Physical Exercise for Patients With Prostate Cancer During Androgen Deprivation Therapy - A Randomized Trial |
Study Start Date : | November 2008 |
Actual Primary Completion Date : | May 2012 |
Actual Study Completion Date : | May 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Strength training group
A four months strength training program during androgen deprivation therapy for prostate cancer patietns.
|
Behavioral: Strength training group
After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
Other Name: Exercise, Physical activity |
No Intervention: Control group
Patients in the control group are not discouraged from performing normal activities. They are however asked not to start a strength training program or increase their activity level in the same period as the experimental group is performing their strength training program. We will offer the control group a modified strength training program after the post-intervention assessment.
|
- lean body mass [ Time Frame: before ADT, before and after the intervention ]
- bone mineral density, fat mass, body mass index, serological outcomes (including lipids, hormones and CRP), physical functioning, psycho-social functioning and muscle cellular outcomes (including muscle fiber size and function) [ Time Frame: before ADT, before and after the intervention ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 75 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Newly diagnosed locally advanced prostate cancer (clinical stage T2 and T3)
- Referred to RH and UUS for radiotherapy
- < 75 years
- Capable of reading and writing Norwegian
- Treating oncologist must approve of the subjects' participation
- Living within approximately 1 hour from Oslo by car or public transportation
Exclusion Criteria:
- Routinely resistance training with manuals
- Medication for osteoporosis (i.e. bisphosphonates)
- Conditions of a severity that contraindicate exercise without adjusted actions
- Mentally incompetent conditions
- Conditions of a severity that complicates the ability to participate in a supervised training program

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00658229
Norway | |
Rikshospitalet- Radiumhospitalet HF | |
Montebello, Oslo, Norway, 0310 |
Principal Investigator: | Lene Thorsen, PhD | Oslo University Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Lene Thorsen, PhD, Oslo University Hospital |
ClinicalTrials.gov Identifier: | NCT00658229 History of Changes |
Other Study ID Numbers: |
REK - 08/212b |
First Posted: | April 14, 2008 Key Record Dates |
Last Update Posted: | October 15, 2012 |
Last Verified: | October 2012 |
Exercise Prostatic Neoplasm Androgen Deprivation |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male |
Prostatic Diseases Androgens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |